- Home
- RAND vs PPCB Comparison
RAND vs PPCB Comparison
Compare RAND & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- PPCB
- Stock Information
- Founded
- RAND 1969
- PPCB 2007
- Country
- RAND United States
- PPCB Australia
- Employees
- RAND N/A
- PPCB N/A
- Industry
- RAND Finance: Consumer Services
- PPCB
- Sector
- RAND Finance
- PPCB
- Exchange
- RAND Nasdaq
- PPCB Nasdaq
- Market Cap
- RAND 44.7M
- PPCB 39.1M
- IPO Year
- RAND N/A
- PPCB N/A
- Fundamental
- Price
- RAND $14.37
- PPCB $1.91
- Analyst Decision
- RAND
- PPCB
- Analyst Count
- RAND 0
- PPCB 0
- Target Price
- RAND N/A
- PPCB N/A
- AVG Volume (30 Days)
- RAND 4.0K
- PPCB 316.9K
- Earning Date
- RAND 11-05-2025
- PPCB 09-30-2025
- Dividend Yield
- RAND 11.24%
- PPCB N/A
- EPS Growth
- RAND N/A
- PPCB N/A
- EPS
- RAND N/A
- PPCB N/A
- Revenue
- RAND $7,966,118.00
- PPCB N/A
- Revenue This Year
- RAND N/A
- PPCB N/A
- Revenue Next Year
- RAND N/A
- PPCB N/A
- P/E Ratio
- RAND N/A
- PPCB N/A
- Revenue Growth
- RAND 1.16
- PPCB N/A
- 52 Week Low
- RAND $13.82
- PPCB $1.25
- 52 Week High
- RAND $31.89
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- RAND 41.83
- PPCB N/A
- Support Level
- RAND $14.27
- PPCB N/A
- Resistance Level
- RAND $15.22
- PPCB N/A
- Average True Range (ATR)
- RAND 0.45
- PPCB 0.00
- MACD
- RAND 0.03
- PPCB 0.00
- Stochastic Oscillator
- RAND 10.21
- PPCB 0.00
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.